← All trials
NCT05345691
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 24, 2022
- Primary completion
- Jun 20, 2024
- Completion date
- Jun 20, 2024
- First posted
- Apr 26, 2022
- Last posted
- May 25, 2022
- Enrollment
- 480
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Biocon LimitedLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.